Who is sponsoring NCT01278940?

NCT01278940 is sponsored by Oslo University Hospital.

What condition does NCT01278940 study?

NCT01278940 studies Malignant Melanoma.

What drugs are being tested in NCT01278940?

Interventions: Dendritic Cells (DC) malignant melanoma, IL-2.

What is the status of NCT01278940?

NCT01278940 is currently COMPLETED.

Last reviewed 2016-08-12 · How we verify

Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

NCT01278940 Phase 1/Phase 2 COMPLETED

PRIMARY OBJECTIVES: Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs . SECONDARY OBJECTIVES:Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response

Details

Lead sponsor	Oslo University Hospital
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	31
Start date	2002-03
Completion	2015-12

Conditions

Malignant Melanoma

Interventions

Dendritic Cells (DC) malignant melanoma
IL-2

Primary outcomes

Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs — Patients are coming every week during 6 weeks.
Biochemistry and hematology results, vital signs and ECOG performance status are measured at those timepoints.